{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:48:50Z","timestamp":1789735730367,"version":"4.0.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cutaneous T-cell lymphomas (CTCLs) are rare malignancies involving primarily the skin. Responses to treatment are usually short-lived in advanced CTCL. The determinants of long-term CTCL control are unclear. Mogamulizumab, an anti-human CCR4 antibody that acts by antibody-dependent cell cytotoxicity against CCR4+ CTCL tumor cells and peripheral memory blood regulatory T cells, has been associated with long-lasting remissions and immune adverse events. Here, we reported skin rashes in 32% of 44 patients with CTCL treated with mogamulizumab, associated with significantly higher overall survival (hazard ratio, 0.16; 0.04-0.73; P = .01). Rash occurred in patients with S\u00e9zary syndrome and was associated with longer time to progression. These rashes were characterized by a CD163+ granulomatous and\/or CD8+ lichenoid skin infiltrate. High-throughput sequencing analysis of T-cell receptor \u03b2 genes in skin and blood flow cytometry confirmed the depletion of CTCL tumor cells, as well as the recruitment of new reactive T-cell clones in skin at the time of skin rash. CXCL9 and CXCL11, two macrophage-derived chemokines that recruit CXCR3+ T cells to skin, were overexpressed in skin rashes. A higher frequency of TIGIT+ and PD1+ exhausted reactive blood T cells was observed at baseline in patients with rash, and this frequency decreased with mogamulizumab treatment. These data are consistent with mogamulizumab-induced long-term immune CTCL control by activation of the macrophage and T-cell responses in patients with rash.<\/jats:p>","DOI":"10.1182\/blood.2021013341","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T20:06:11Z","timestamp":1639512371000},"page":"1820-1832","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-6211","authenticated-orcid":false,"given":"Ad\u00e8le","family":"de Masson","sequence":"first","affiliation":[{"name":"Dermatology Department, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France;"},{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1705-7543","authenticated-orcid":false,"given":"Delphine","family":"Darbord","sequence":"additional","affiliation":[{"name":"Pathology Department and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7197","authenticated-orcid":false,"given":"Gabor","family":"Dobos","sequence":"additional","affiliation":[{"name":"Dermatology Department, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France;"},{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Boisson","sequence":"additional","affiliation":[{"name":"Tumor Genomics and Pharmacology Department, AP-HP, Saint Louis Hospital, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-8742","authenticated-orcid":false,"given":"Marie","family":"Roelens","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM UMR 1160, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ram-Wolff","sequence":"additional","affiliation":[{"name":"Dermatology Department, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5087-4414","authenticated-orcid":false,"given":"Charles","family":"Cassius","sequence":"additional","affiliation":[{"name":"Dermatology Department, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France;"},{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2139-0357","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Le Buanec","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6361-1878","authenticated-orcid":false,"given":"Pierre","family":"de la Grange","sequence":"additional","affiliation":[{"name":"Genosplice, Paris,\u00a0France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6706-7424","authenticated-orcid":false,"given":"Fan\u00e9lie","family":"Jouenne","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"},{"name":"Tumor Genomics and Pharmacology Department, AP-HP, Saint Louis Hospital, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Louveau","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"},{"name":"Tumor Genomics and Pharmacology Department, AP-HP, Saint Louis Hospital, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Sadoux","sequence":"additional","affiliation":[{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"},{"name":"Tumor Genomics and Pharmacology Department, AP-HP, Saint Louis Hospital, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-David","family":"Bouaziz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France;"},{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Marie-Cardine","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"Dermatology Department, Assistance Publique\u2013H\u00f4pitaux de Paris (AP-HP), Saint Louis Hospital, Paris, France;"},{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-7534","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Moins-Teisserenc","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM UMR 1160, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mourah","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"},{"name":"Tumor Genomics and Pharmacology Department, AP-HP, Saint Louis Hospital, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-7431","authenticated-orcid":false,"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France;"},{"name":"INSERM\u00a0UMRS 976 \u201cHuman Immunology, Pathophysiology and Immunotherapy\u201d, Institut de Recherche Saint-Louis, Paris, France;"},{"name":"Pathology Department and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2022032421390119000_B1","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022032421390119000_B2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"12","key":"2022032421390119000_B3","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","article-title":"Histopathologic characterization of mogamulizumab-associated rash","volume":"44","author":"Wang","year":"2020","journal-title":"Am J Surg Pathol."},{"issue":"6","key":"2022032421390119000_B4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or S\u00e9zary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol."},{"issue":"2","key":"2022032421390119000_B5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with S\u00e9zary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br J Dermatol."},{"issue":"2","key":"2022032421390119000_B6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1684\/ejd.2021.4002","article-title":"Mogamulizumab-induced vitiligo in patients with S\u00e9zary syndrome: three cases","volume":"31","author":"Algarni","year":"2021","journal-title":"Eur J Dermatol."},{"issue":"10","key":"2022032421390119000_B7","doi-asserted-by":"crossref","first-page":"adv00158","DOI":"10.2340\/00015555-3527","article-title":"Mogamulizumab-induced mucocutaneous lichenoid reaction: a case report and short review","volume":"100","author":"Trager","year":"2020","journal-title":"Acta Derm Venereol."},{"issue":"18","key":"2022032421390119000_B8","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol."},{"key":"2022032421390119000_B9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides\u00a0and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC Cutaneous Lymphoma Task Force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer."},{"issue":"1","key":"2022032421390119000_B10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/jid.2014.356","article-title":"CD158k is a reliable marker for diagnosis of S\u00e9zary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells","volume":"135","author":"Moins-Teisserenc","year":"2015","journal-title":"J Invest Dermatol."},{"issue":"440","key":"2022032421390119000_B11","doi-asserted-by":"crossref","first-page":"eaar5894","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-throughput sequencing of the T cell receptor \u03b2 gene identifies aggressive early-stage mycosis fungoides","volume":"10","author":"de Masson","year":"2018","journal-title":"Sci Transl Med."},{"issue":"2","key":"2022032421390119000_B12","doi-asserted-by":"crossref","first-page":"giab002","DOI":"10.1093\/gigascience\/giab002","article-title":"The Gene Expression Deconvolution Interactive Tool (GEDIT): accurate cell type quantification from gene expression data","volume":"10","author":"Nadel","year":"2021","journal-title":"GigaScience."},{"issue":"1","key":"2022032421390119000_B13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/1471-2164-14-527","article-title":"Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients","volume":"14","author":"Swindell","year":"2013","journal-title":"BMC Genomics."},{"issue":"14","key":"2022032421390119000_B14","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1158\/1078-0432.CCR-19-0148","article-title":"Single-cell lymphocyte heterogeneity in advanced cutaneous T-cell lymphoma skin tumors","volume":"25","author":"Gaydosik","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2022032421390119000_B15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jaci.2020.01.042","article-title":"Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis","volume":"145","author":"He","year":"2020","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"2022032421390119000_B16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell."},{"issue":"1","key":"2022032421390119000_B17","doi-asserted-by":"crossref","first-page":"124233","DOI":"10.1172\/jci.insight.124233","article-title":"Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma","volume":"4","author":"Vieyra-Garcia","year":"2019","journal-title":"JCI Insight."},{"issue":"2","key":"2022032421390119000_B18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2022032421390119000_B19","doi-asserted-by":"crossref","first-page":"108115","DOI":"10.1016\/j.celrep.2020.108115","article-title":"Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to avelumab treatment","volume":"32","author":"Qu","year":"2020","journal-title":"Cell Rep."},{"key":"2022032421390119000_B20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2013 a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"2022032421390119000_B21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","article-title":"Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation","volume":"194","author":"Flier","year":"2001","journal-title":"J Pathol."},{"issue":"12","key":"2022032421390119000_B22","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol."},{"issue":"3","key":"2022032421390119000_B23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica."},{"issue":"6","key":"2022032421390119000_B24","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S\u00e9zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"56","author":"Domingo-Domenech","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"214","key":"2022032421390119000_B25","doi-asserted-by":"crossref","first-page":"214ra171","DOI":"10.1126\/scitranslmed.3007420","article-title":"Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma","volume":"5","author":"Weng","year":"2013","journal-title":"Sci Transl Med."},{"issue":"1","key":"2022032421390119000_B26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjd.20708","article-title":"Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series","volume":"186","author":"Trum","journal-title":"Br J Dermatol."},{"issue":"117","key":"2022032421390119000_B27","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med."},{"issue":"1","key":"2022032421390119000_B28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1749-6632.2001.tb03708.x","article-title":"Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas","volume":"941","author":"Bagot","year":"2001","journal-title":"Ann N Y Acad Sci."},{"issue":"1","key":"2022032421390119000_B29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20011097","article-title":"Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells","volume":"195","author":"Dhodapkar","year":"2002","journal-title":"J Exp Med."},{"issue":"2","key":"2022032421390119000_B30","doi-asserted-by":"crossref","first-page":"e002045","DOI":"10.1136\/jitc-2020-002045","article-title":"CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer","volume":"9","author":"Marcovecchio","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"5","key":"2022032421390119000_B31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"2022032421390119000_B32","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/bloodadvances.2020001641","article-title":"Robust CD8+\u00a0T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma","volume":"4","author":"Saito","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"2022032421390119000_B33","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol."},{"issue":"9","key":"2022032421390119000_B34","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","article-title":"Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol."},{"issue":"12","key":"2022032421390119000_B35","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood."},{"issue":"6","key":"2022032421390119000_B36","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","article-title":"Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma","volume":"63","author":"Kim","year":"2010","journal-title":"J Am Acad Dermatol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/12\/1820\/1882213\/bloodbld2021013341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/12\/1820\/1882213\/bloodbld2021013341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:41:59Z","timestamp":1648158119000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/12\/1820\/483061\/Macrophage-derived-CXCL9-and-CXCL11-T-cell-skin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021013341","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}